Merck & Co.
AWARDS
NEWS
While Humira being the top-selling drug is on the decline due to increased competition and expiring patents, Keytruda is set to take the number-one position.
PDS0101- KEYTRUDA® (pembrolizumab) Combination to be Evaluated in First Line Treatment of Metastatic Head and Neck Cancer
Merck’s vaunted checkpoint inhibitor Keytruda combined with chemotherapy proved to be more efficacious than chemotherapy alone as neoadjuvant therapy in pre- and post-surgery triple-negative breast cancer patients.
Nicholas Kartsonis, head of clinical research in infectious diseases and vaccines at Merck Research Laboratories, noted that additional treatment options are needed for critically ill patients with respiratory infections.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
Merck had the unusual case of having its checkpoint inhibitor Keytruda (pembrolizumab) approved simultaneously in three countries for advanced endometrial carcinoma.
JOBS
IN THE PRESS